SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
CART-ddBCMA, ki se trenutno preiskuje v ključni preskušanji faze 2, je Arcellxova terapija T-celic, ki uporablja novo sintetično vezivo podjetja, D-domeno. Kite in Arcellx bosta skupaj pospeševala in komercializirala sredstvo CART-ddBCMA v ZDA, Kite pa bo komercializiral izdelek zunaj ZDA
CAR T-celična terapija je med prelomnimi zdravili za nekatere vrste krvnega raka. V teku je več kot 750 kliničnih preskušanj in CAR T-Cell terapija na Kitajskem trenutno. Pacienti, ki se želijo vpisati, se lahko obrnejo na CancerFax telefon za pomoč bolnikom na WhatsApp +91 96 1588 1588 ali na elektronski naslov info@cancerfax.com.
O Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multipli mielom (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk mielodisplastični sindrom, initiated in the fourth quarter of 2022.
Glede Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
O znanosti Gilead
Gilead Sciences, Inc. je biofarmacevtsko podjetje, ki si več kot tri desetletja prizadeva in dosega preboje v medicini s ciljem ustvariti bolj zdrav svet za vse ljudi. Podjetje je zavezano razvoju inovativnih zdravil za preprečevanje in zdravljenje življenjsko nevarnih bolezni, vključno z virusom HIV, virusnim hepatitisom in rakom. Gilead deluje v več kot 35 državah po vsem svetu, s sedežem v Foster Cityju v Kaliforniji. Gilead Sciences je leta 2017 kupil Kite.
